
APC Fund

Professional Work

12-14-2023

E-cigarette use and respiratory symptoms in adults: A systematic review and meta-analysis

Mohammed M. Alqahtani

Faraj K. Alenezi

Mohammed A. Almeshari

Abdullah M. Alanazi

Ziyad Ben Taleb

See next page for additional authors

Follow this and additional works at: <https://digitalcommons.library.uab.edu/apc>



Part of the [Medicine and Health Sciences Commons](#)

Authors

Mohammed M. Alqahtani, Faraj K. Alenezi, Mohammed A. Almeshari, Abdullah M. Alanazi, Ziyad Ben Taleb, Mohammad E Ebrahimi Kalan, Mary P. Martinasek, Rheese J. McNab, Rachel Culbreth, Mansour Alotaibi, Hassan Alijohani, Lynda T. Goodfellow, Taha T. Ismaeil, Saleh S. Algarni, Tareq F. Alotaibi, Mobarek K. Alqahtani, Hamoud Al-Ajel, Khalid S. Alwadeai, Nafea S. Almutairi, and Eric Ford

E-cigarette use and respiratory symptoms in adults: A systematic review and meta-analysis

Mohammed M. Alqahtani^{1,2,3}, Faraj K. Alenezi^{4,5}, Mohammed A. Almeshari⁶, Abdullah M. Alanazi^{1,2}, Ziyad Ben Taleb⁷, Mohammad E. Ebrahimi Kalan⁸, Mary P. Martinasek⁹, Rheese J. McNab⁹, Rachel Culbreth¹⁰, Mansour Alotaibi¹¹, Hassan Aljohani^{1,2}, Lynda T. Goodfellow¹², Taha T. Ismaeil^{1,2}, Saleh S. Algarni^{1,2}, Tareq F. Alotaibi^{1,2}, Mobarak K. Alqahtani^{1,2}, Hamoud Al-Ajel^{13,14}, Khalid S. Alwadeai⁶, Nafea S. Almutairi¹⁵, Eric Ford¹⁶

ABSTRACT

INTRODUCTION Electronic cigarette (e-cigarette) use is gaining popularity among adults. Monitoring e-cigarette-induced respiratory symptoms is crucial for both clinical and regulatory purposes. We systematically reviewed the current literature to understand the prevalence of respiratory symptoms among exclusive e-cigarette users, dual users, and former smokers.

METHODS Databases searched included PubMed, CINAHL, Cochrane Library, Embase, and Scopus. We included all English-language, empirical quantitative articles that explored the prevalence of e-cigarette-related respiratory symptoms. Random-effects models were utilized in conducting the meta-analyses. The quality of identified studies was evaluated using the NIH Study Quality Assessment Tools. This study is registered with PROSPERO (#CRD42020165973).

RESULTS The literature search identified 1240 references. After removing duplicates and screening for eligibility, 168 studies were included in the final review. The majority of included studies reported a wide range of adverse respiratory symptoms. The respiratory symptoms were prevalent among the exclusive e-cigarette users, dual users, and those who switched from combustible cigarettes to e-cigarettes. Further, out of the RCT studies, 5 were rated as good quality, while 3 were rated as fair. Among the observational studies, 24 were rated as good quality, and 9 were rated as fair. The two experimental studies were both rated as fair quality.

CONCLUSIONS Continued monitoring of respiratory symptoms among e-cigarette users is warranted. Due to the heterogeneity and inconsistencies among studies, which limit result interpretation and highlight the need for studies assessing causal inference, further research using robust study designs is essential. This will provide clinicians with comprehensive knowledge about the potential respiratory risks of e-cigarette use.

AFFILIATION

1 Department of Respiratory Therapy, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

2 King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

3 Population Science, American Cancer Society, Atlanta, United States

4 Department of Anaesthesia Technology, College of Applied Medical Sciences, King Saud Bin Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia

5 Birmingham Acute Care Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

6 Department of Rehabilitation Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia

7 Public Health Program, Department of Kinesiology, College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, United States

8 School of Health Professions, Eastern Virginia Medical School, Norfolk, United States

9 Department of Health Sciences and Human Performance, University of Tampa, Tampa, United States

10 Department of Respiratory Therapy, Georgia State University, Atlanta, United States

11 Department of Physical Therapy, Northern Border

Tob. Induc. Dis. 2023;21(December):168

<https://doi.org/10.18332/tid/174660>

INTRODUCTION

It is estimated that there were 5.66 million adults in the US who were currently (some days or every day) using e-cigarettes in 2019¹. Among current e-cigarette users, more than 2.21 million were current cigarette smokers, more than 2.14 million were former smokers, and more than 1.30 million were never smokers¹.

The impact of long-term dual use poses a public health concern, given the accumulating evidence regarding the detrimental health effects associated with

the use of e-cigarette and traditional cigarette types^{2,3}. Accordingly, there is a pressing need for a more comprehensive understanding of the broad health effects associated with e-cigarettes and the dual use of e-cigarettes and cigarettes, as the potential harms have not been comprehensively reported⁴.

Research on the health effects of e-cigarette use has been increasing and systematic reviews summarized studies on toxic constituents. For example, recent systematic reviews focused on toxic constituents in e-cigarette aerosols⁵⁻⁷, carcinogen biomarkers and the association with bladder cancer⁸, oral health^{9,10}, the impact of e-cigarettes on pregnancy¹¹, and cardiovascular health¹². While several studies have examined the pulmonary effects of e-cigarettes^{13,14}, this evidence has not been systematically summarized and there is a lack of knowledge regarding the potential impact of e-cigarette on pulmonary health. Specifically, the effects of e-cigarettes and dual usage of e-cigarettes and traditional cigarettes on pulmonary health and respiratory symptoms merit further research and systematic review, given the fast evolution of e-cigarettes¹⁵.

Some evidence suggests an association between e-cigarette use and pulmonary illness¹⁶. Mechanisms of lung injury following e-cigarette usage are being studied with greater frequency. One study found numerous nanoparticles and oxidants present in e-cigarette aerosols, which in turn cause mitochondrial stress, DNA fragmentation, and inflammatory stress on lung cells¹⁷. A recent US Centers for Disease Control and Prevention (CDC) report indicated that aerosols from e-cigarettes may also contain lead, carcinogens, and volatile organic compounds¹⁸. These compounds can potentially damage lung and neurocognitive development in humans, which is already proven in animal studies¹⁹. Using e-cigarettes has also been known to worsen asthma symptoms, which is concerning, in particular for youth, due to a recent study showing that 22.5% of asthmatic adults aged ≥ 18 years reported currently using e-cigarettes²⁰.

In this study, we conducted a systematic review of the current empirical literature on respiratory symptoms in three groups: exclusive e-cigarette users, dual users of e-cigarettes and traditional cigarettes, and those who have switched from traditional cigarettes to e-cigarettes. This research provides valuable insights into

the effects of respiratory symptoms, which could serve as a guiding resource for respiratory therapists, pulmonologists, and other healthcare professionals.

METHODS

A systematic review of the empirical literature was conducted by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol (Supplementary file). We have assessed the prevalence of respiratory symptoms among three groups; these groups included exclusive e-cigarette users, dual users (both e-cigarette and traditional cigarette users), and former smokers transitioning to e-cigarettes in an attempt to quit smoking. Therefore, we conducted a meta-analysis to examine the differences in respiratory symptom incidences among these three groups. The protocol for this study was registered with PROSPERO (#CRD42020165973).

Data sources

Relevant publications were located through a literature search from 24 September 2021, and again on 19 April 2023. To address the research question of respiratory symptoms in e-cigarette users, a combination of database-specific subject headings and keywords were used as search strategies (Supplementary file), covering the concepts of respiratory symptoms and e-cigarettes in PubMed, Embase, CINAHL, CENTRAL, and Scopus. All articles in the English language were included with no date limits (Supplementary File).

University, Arar, Saudi Arabia

¹² Lewis College of Nursing and Health Professions, Georgia State University, Atlanta, United States

¹³ Department of Community Health Sciences, College of Applied Medical Sciences, King Saud University, Al-Riyadh, Saudi Arabia

¹⁴ Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, United States

¹⁵ Department of Basic Sciences, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

¹⁶ Department of Health Care Organization and Policy, University of Alabama at Birmingham, Birmingham, United States

CORRESPONDENCE TO

Mohammed M. Alqahtani. Department of Respiratory Therapy, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), 13241 Riyadh, Saudi Arabia. E-mail: qahtanimoh@ksau-hs.edu.sa
ORCID ID: <https://orcid.org/0000-0003-1656-0881>

KEYWORDS

e-cigarette, respiratory symptoms, systematic review

Received: 22 January 2023

Revised: 26 October 2023

Accepted: 30 October 2023

Study selection

Two reviewers (MA and EF) individually screened all titles and abstracts based on inclusion and exclusion criteria. Next, they independently reviewed the full text of all articles that passed the initial review, and conflicts were resolved by discussion with a third reviewer (FA).

Inclusion criteria

In this research review, the focus was primarily on observational studies, which include cohort, case-control, and cross-sectional methodologies, as well as intervention studies, encompassing both randomized controlled and experimental designs. The participants under consideration were adults aged ≥ 18 years, specifically those who reported either current or past use of e-cigarettes. Furthermore, only those studies that reported explicitly on respiratory symptoms were considered. These symptoms are defined as breathlessness, dyspnea, breathing difficulties, wheeze, cough, sputum, and phlegm. To assist in understanding the specifics of the studies included, they were categorized using the PICO criteria. These criteria delineate the population in question, the intervention or comparative component of the study, and the outcome of interest, which in this context relates to respiratory symptoms.

Exclusion criteria

This research review excluded several types of publications and studies. Specifically, book chapters, published systematic reviews (although their reference lists were screened for potential inclusions), non-English manuscripts, and conference abstracts lacking full-text availability, were excluded. Additionally, studies that failed to report e-cigarette use status and only reported on combusted cigarette smoking or other tobacco products like hookah, cigarette, cigarillos, chewing tobacco, snuff, snus, or dissolvable tobacco products, were not considered. Similarly, research not indicating any of the respiratory symptoms or those conducted using animal samples were also excluded from the review.

Data extraction and quality assessment

For each included study, two reviewers independently extracted data on all outcomes. They also extracted data

on the manuscript's research design (interventional, cross-sectional, observational, or experimental), study population, participant age, and e-cigarette/traditional cigarette use. The risk of bias (ROB) in individual studies was assessed independently by two reviewers at both study and outcome levels using NIH Study Quality Assessment Tools which are guidelines by the National Institutes of Health for assessing the rigor of various research studies. They cater to different study designs, including randomized controlled trials, observational studies, and systematic reviews. These tools guide users in identifying biases and evaluating overall study quality, ensuring reliable research assessments, and rate studies as having low ROB if they had robust assessment and adjustment for study characteristics.

Data synthesis and analysis

Random-effects models were utilized in conducting the meta-analyses. Heterogeneity among the included studies was assessed using the I^2 statistic. All analyses were conducted using the R software.


RESULTS

Study characteristics

Of the 168 full-text articles assessed for eligibility, 43 studies met our inclusion criteria from eleven different countries (Supplementary file). Among these, 19 studies were conducted in the United States²¹⁻³⁹, seven in the United Kingdom⁴⁰⁻⁴⁶ and four in Italy⁴⁷⁻⁵⁰. Other countries included Poland⁵¹, Greece^{52,53}, Malaysia^{54,55}, Australia⁵⁶, Canada⁵⁷, Saudi Arabia⁵⁸ and Indonesia⁵⁹. One multi-country study included a survey of respondents from France, Canada, Belgium, and Switzerland⁶⁰. Two studies used data sources such as a worldwide survey and Internet forums to recruit e-cigarette users^{61,62}.

The age groups for these studies ranged from young adults (18 years of age) to older adults (65 years). Of the 43 studies reviewed for study design, 8 were randomized controlled trials (RCTs)^{25,31,40,42-45,47}, 19 were cross-sectional studies^{22,24,29,30,35,37-39,41,51-53,55,56,58-61,63}, and two were experimental studies^{27,28}. Two studies used an integrated, mixed-method participatory approach called concept mapping^{36,62} and another three studies used a retrospective study design^{23,33,57}. The remaining

Figure 1. Forest plot of respiratory symptom prevalence among exclusive, dual, and transitioning e-cigarette users



Each line represents a study with the square indicating prevalence and line width representing the 95% CI. Diamond markers indicate pooled prevalence for user categories.

nine studies are categorized as longitudinal cohort studies^{21,26,34,48,50,54,64–66} (Supplementary file).

Of the 43 studies that were reviewed, 14 presented data on studies with less than 100 subjects^{22,25,27,28,31,34,45,48–50,52,59,60,62} while eleven studies presented data with sample sizes that ranged from 100 to just under 1000 subjects^{39,40,42–44,47,53,54,56,58,66}. Finally, 15 studies gathered data from larger sample sizes of over 1000 subjects using different data sources such as surveys and online forum^{21,24,26,30,35–38,41,51,55,57,61,63,64}.

Quality assessment and risk of bias

As the studies were cohort, cross-sectional, and randomized controlled trials, all included articles were evaluated using the NIH quality assessment tools. Five studies out of the RCT studies were rated as good quality, whereas three were rated as fair. Twenty-four observational studies were rated as good quality, nine as fair, and finally, the two experimental studies were rated as fair (Supplementary file Figure 1).

Meta-analysis of respiratory symptoms among different e-cigarette users: Exclusive e-cigarette users, dual users and former smokers transitioning to e-cigarettes

Any reported respiratory symptoms

In the meta-analysis evaluating the prevalence of any

respiratory symptoms among exclusive e-cigarette users, a total of 34493 individuals from three distinct studies^{26,38,55} were included. Utilizing a random-effects model, we determined the pooled prevalence of any respiratory symptoms to be 22% (95% CI: 0.06–0.56). High heterogeneity was observed across the studies ($I^2=98\%$, $p<0.01$) (Figure 1).


No meta-analysis was conducted on dual e-cigarette users as there was only one study⁵⁵ that reported it. A total of 524 individuals were included in that study and the prevalence of any respiratory symptoms was 20%.

Two studies^{43,55} involving 232 transitioning e-cigarette users were included in the meta-analysis of any respiratory symptoms prevalence, resulting in a pooled prevalence of 34% (95% CI: 0.00–1.00). A high level of heterogeneity was observed among the studies ($I^2=94\%$, $p<0.01$) (Figure 1).

Cough

In the meta-analysis of cough prevalence among dual e-cigarette users, data from 5363 individuals across 10 studies were included^{21,22,24,34,39,52, 54,57,61,66}. A random-effects model resulted in a pooled cough prevalence of 26% (95% CI: 0.16–0.41). A high level of heterogeneity was observed among the studies ($I^2=98\%$, $p<0.01$) (Figure 2).

Figure 2. Forest plot of cough prevalence among exclusive, dual, and transitioning e-cigarette user



Each horizontal line corresponds to a specific study. The square marker on each line indicates the reported prevalence for that study, while the width of the line represents its 95% CI. At the end of the lines for each user category, a diamond marker consolidates and indicates the pooled prevalence derived from the studies within that category.

The prevalence of cough among exclusive e-cigarette users encompassed a total of 54658 individuals from 12 separate studies^{21,24,29,38,47,51,54,57-59,63,66}. A random-effects model was employed, revealing a pooled prevalence of cough at 21% (95% CI: 0.14–0.31). A significant heterogeneity was identified across the studies ($I^2=95\%$, $p<0.001$) (Figure 2).


The cough prevalence, which encompassed 13 studies^{21,31,40,42-45,48,50,52,53,61,65} and a total of 17236

transitioning e-cigarette users, utilized a random-effects model to determine a pooled cough prevalence of 18% (95% CI: 0.14–0.23). A high level of heterogeneity was observed among the studies ($I^2=88\%$, $p<0.01$) (Figure 2).

Phlegm

In the meta-analysis focusing on the prevalence of phlegm among exclusive e-cigarette users, we

Figure 3. Forest plot of phlegm prevalence among exclusive, dual, and transitioning e-cigarette users



Each line represents a study's findings, with square markers indicating prevalence and line width the 95% CI. Diamond markers summarize pooled prevalence.

included a total of 897 individuals from two distinct studies^{24,57}. The pooled prevalence of phlegm was found to be 24% (95% CI: 0.11–0.46). We noted a moderate degree of heterogeneity across the studies ($I^2=71\%$, $p=0.07$) (Figure 3).

The prevalence of phlegm among dual e-cigarette users included 215 individuals' data from three studies^{22,24,57}. The random-effects model yielded a pooled phlegm prevalence of 20% (95% CI: 0.01–0.85). The heterogeneity among studies was substantial ($I^2=88\%$, $p<0.01$) (Figure 3).

In the transitioning e-cigarette users, data from two studies^{42,43} involving 486 yielded a pooled prevalence of 29% (95% CI: 0.01–0.96). High heterogeneity across the studies was observed ($I^2=88\%$, $p<0.01$) (Figure 3).

Shortness of breath

In the meta-analysis investigating the prevalence of shortness of breath among dual e-cigarette users included 4697 individuals from seven studies^{22,39,52,54,57,61,66}. The pooled prevalence of shortness of breath was 12% (95% CI: 0.03–0.36)

using a random-effects model. A high heterogeneity was noted ($I^2=99\%$, $p<0.01$) (Figure 4).

In exclusive e-cigarette users, data from 35747 individuals across seven individual studies were incorporated^{37,38,47,51,54,57,66}. The pooled prevalence of shortness of breath was found to be 20% (95% CI: 0.05–0.54). The studies demonstrated a high degree of heterogeneity ($I^2=99\%$, $p<0.01$).


In the transitioning e-cigarette users, the shortness of breath prevalence meta-analysis encompassed five studies^{37,42,43,52,61} and 16882 individuals. The pooled prevalence was 12% (95% CI: 0.01–0.63) and high level of heterogeneity was found ($I^2=100\%$, $p<0.01$) (Figure 4).

Wheezing

The meta-analysis of wheezing prevalence among dual e-cigarette users included 1274 individuals from five studies^{21,22,24,39,57}. The pooled wheezing prevalence was 21% (95% CI: 0.08–0.43) using a random-effects model. High heterogeneity was observed ($I^2=88\%$, $p<0.01$) (Supplementary file Figure 2).

Among exclusive e-cigarette users, data from

Figure 4. Forest plot of shortness of breath prevalence among dual, exclusive, and transitioning e-cigarette users



Each study is represented by a line, with square markers indicating the reported prevalence and the line width showing the 95% CI. Diamond markers consolidate the pooled prevalence for each user category.

20807 individuals across six separate studies were included^{21,24,26,35,57,63}. Using a random-effects model, the pooled prevalence of wheezing was 19% (95% CI: 0.12–0.30). The heterogeneity among studies was high ($I^2=93\%$, $p<0.01$).

Wheezing prevalence was analyzed from three studies^{21,42,43} which included 585 transitioning e-cigarette users. The pooled prevalence stood at 17% (95% CI: 0.11–0.24). The heterogeneity was found to be low ($I^2=0\%$, $p=0.91$) (Supplementary file Figure 2).

Oropharyngeal symptoms

In the meta-analysis of oropharyngeal symptom prevalence among dual e-cigarette users, data from

4521 individuals across four studies^{39,41,52,61} were included. The pooled prevalence of oropharyngeal symptoms was 3% (95% CI: 0.01–0.13) using a random-effects model. A moderate level of heterogeneity was observed ($I^2=78\%$, $p<0.01$) (Supplementary file Figure 3).

No meta-analysis of the prevalence of oropharyngeal symptoms among exclusive e-cigarette users was conducted as only one study reported it⁵⁸. However, data from 401 individuals from the single study showed a prevalence of oropharyngeal symptoms of 7%.

The prevalence of oropharyngeal symptoms was analyzed across six studies^{41,48–50,52,61} with 17091 transitioning e-cigarette users, resulting in a pooled

prevalence of 4% (95% CI: 0.01–0.15). Heterogeneity was found to be high ($I^2=91\%$, $p<0.01$) (Supplementary file Figure 3).

Dry mouth

The meta-analysis of dry mouth symptom prevalence among dual e-cigarette users incorporated 3976 individuals from three studies^{54,61,66}. The pooled prevalence of dry mouth symptoms was 52% (95% CI: 0.27–0.76) using a random-effects model. A high heterogeneity was noted ($I^2=96\%$, $p<0.01$) (Supplementary file Figure 4).

For the prevalence of dry mouth symptoms among exclusive e-cigarette users, a total of 840 individuals were included from four studies^{47,54,58,66}. The pooled prevalence, based on a random-effects model, was 37% (95% CI: 0.15–0.67). The studies displayed high heterogeneity ($I^2=95\%$, $p<0.01$) (Supplementary file Figure 4).

Four studies^{48,50,61,65}, involving a total of 15770 transitioning e-cigarette users, were included in the meta-analysis of dry mouth symptoms prevalence. The pooled prevalence was 15% (95% CI: 0.03–0.50). The heterogeneity was found to be high ($I^2=87\%$, $p<0.01$) (Supplementary file Figure 4).

Chest pain

In the meta-analysis of chest pain symptom prevalence among dual e-cigarette users, a total of 4361 individuals were included from four studies^{22,39,52,61}. The pooled prevalence of chest pain symptoms was 5% (95% CI: 0.00–0.38) using a random-effects model. The studies showed a high level of heterogeneity ($I^2=99\%$, $p<0.01$) (Supplementary file Figure 5).

The prevalence of chest pain symptoms among exclusive e-cigarette users, incorporated data from 817 individuals from three studies^{26,29,37}. The random-effects model indicated a pooled prevalence of chest pain symptoms at 22% (95% CI: 0.04–0.66). High heterogeneity was observed among the studies ($I^2=95\%$, $p<0.01$) (Supplementary file Figure 5).

The meta-analysis of chest pain symptoms prevalence included five studies^{37,42,52,53,61} and 16945 transitioning e-cigarette users; the pooled prevalence was found to be 7% (95% CI: 0.01–0.32). High heterogeneity was noted ($I^2=100\%$, $p<0.01$) (Supplementary file Figure 5).

Nasopharyngeal

The prevalence of nasopharyngeal symptoms was analyzed from two studies^{44,45} which included 515 transitioning e-cigarette users. The meta-analysis yielding a pooled prevalence of 19% (95% CI: 0.00–0.99). High level of heterogeneity was observed ($I^2=97\%$, $p<0.01$) (Supplementary file Figure 6). No meta-analysis of nasopharyngeal symptoms was conducted for exclusive e-cigarette users or dual users due to lack of studies reporting it.

Throat irritation

Lastly, the meta-analysis of throat irritation symptoms prevalence among dual e-cigarette users included 4836 individuals from seven studies^{34,39,41,52,54,61,66}. The pooled prevalence of throat irritation symptoms was 15% (95% CI: 0.05–0.36) using a random-effects model (Supplementary file Figure 7).

The meta-analysis on the prevalence of throat irritation symptoms among exclusive e-cigarette users incorporated data of 459 individuals from four studies^{47,54,59,66}. Utilizing a random-effects model, the pooled prevalence of throat irritation was found to be 24% (95% CI: 0.04–0.69).

Ten studies^{31,40,41,44,48,50,52,53,61,65} involving 17737 transitioning e-cigarette users were analyzed. The pooled prevalence was found to be 17% (95% CI: 0.07–0.34). High-level heterogeneity was found ($I^2=96\%$, $p<0.01$) (Supplementary file Figure 7).

Overall, a significant difference was observed in the incidence of phlegm, throat irritation, chest pain, dry mouth, shortness of breath, oropharyngeal symptoms, wheezing, cough, and any respiratory symptoms among the three distinct groups: exclusive e-cigarette users, dual users, and former smokers transitioning to e-cigarette use.

DISCUSSION

This review contributes to the literature and knowledge surrounding the association between e-cigarette use and the manifestation of respiratory symptoms in adults. While animal studies have highlighted the deleterious effects of e-cigarettes on the pulmonary system, there remains a gap in our understanding of the association between e-cigarette-induced respiratory symptoms and usage status in human subjects. For instance, among current dual

users, it is ambiguous whether respiratory symptoms are a consequence of e-cigarette use or traditional cigarette smoking. Further, it is uncertain whether existing symptoms are remnants of past smoking habits that have persisted into current e-cigarette use among former smokers. Therefore, it is crucial to conduct studies with robust research designs to track these symptoms longitudinally to determine the temporal relationships between e-cigarette use and the incidence of respiratory symptoms among different e-cigarette users.

Overall, our review found that e-cigarette users reported presence of respiratory symptoms. In our comprehensive analysis, those who exclusively used e-cigarettes displayed significant occurrences of different respiratory issues such as coughing, phlegm production, breathing difficulties, wheezing, dry mouth, chest discomfort, and irritation in the throat. Moreover, our analysis encompassed several studies that examined respiratory symptoms in individuals who used both e-cigarettes and cigarettes; the results indicated significant instances of cough, phlegm, shortness of breath, wheezing, dry mouth, chest pain, and throat irritation. The meta-analysis revealed the following incidences of respiratory symptoms among transitioning e-cigarette users: cough, phlegm, shortness of breath, any respiratory symptoms, wheezing, oropharyngeal symptoms, dry mouth symptoms, nasopharyngeal symptoms, chest pain symptoms, and throat irritation symptoms. These data suggest a significant impact of e-cigarette usage on respiratory health, underlining the need for further investigation.

Many studies reported different respiratory symptoms, strongly suggesting the toxic effects of e-cigarette usage that span across multiple reported symptoms^{10,18,67,68}. The co-occurrence of multiple symptoms across e-cigarette user categories emphasizes the potentially harmful effects of e-cigarettes. It is noteworthy that individuals who only used e-cigarettes and were not former traditional smokers (exclusive only e-cigarette users) also experienced adverse respiratory symptoms, including increased cough, dry mouth/mouth irritation, phlegm, wheezing, shortness of breath, chest pain, and palpitations^{20,69}. As demonstrated previously by animal models, e-cigarette exposure is linked to an increase

in oxidative stress and inflammatory cytokines in bronchoalveolar lavage samples, increased mucus production, and impaired pulmonary immunological function⁷⁰. Thus, it is not surprising that human self-reported respiratory symptoms often include multiple, overlapping symptoms from e-cigarettes. Future longitudinal studies need to examine the development of symptoms across the life course of e-cigarette users, particularly since these devices have only emerged in recent years and diversifying at a rapid pace.

Reported respiratory symptoms among dual users is concerning. In this review, our meta-analysis encompassed multiple studies examining respiratory symptoms among dual e-cigarette users, revealing significant incidences of cough, phlegm, shortness of breath, and wheezing. These results, along with data on other symptoms such as dry mouth, chest pain, and throat irritation, suggest a notable impact of dual e-cigarette usage on respiratory health, which could also be an effect of the high nicotine levels from using both traditional cigarettes and e-cigarettes simultaneously^{22,24,37,39,41,52,54,61,64,66}. Although it is hard to conclude the origin of the respiratory symptoms among dual users, it is known that e-cigarettes have an abundance of other respiratory system irritants such as carbonyls (e.g. aldehydes), volatile organic compounds (e.g. acrolein)⁷¹. Because of the potential synergistic effects of e-cigarette and traditional cigarette dual usage, cessation interventions and primary prevention education are urgently needed. Thus, interventions which address the potential comorbidities and cultural considerations of dual users may be beneficial.

There is a pressing need for research to discern the long-term impact of early e-cigarette initiation on pulmonary health throughout the life course, particularly among youth who introduce e-cigarettes as their first tobacco products.

Currently, although researchers are somewhat divided regarding whether e-cigarettes can or should be used as an aid for smoking cessation, in fact, studies have shown that e-cigarettes provide mixed results in terms of smoking cessation^{46,72}. While e-cigarettes were initially marketed as a smoking cessation tool, it is clear that e-cigarettes are not harmless and the uptake among current smokers often results in dual use rather than cessation of tobacco altogether^{73,74}.

Proper education on adequate smoking cessation tools is needed for current smokers to correct the inaccurate marketing messages of e-cigarettes as cessation tools^{73,74}, which is not an approved cessation tool in the US and several other nations.

Future research should include more long-term studies of animal models, utilizing predictive modeling for respiratory symptoms of e-cigarette users across the life course. Interventions are also warranted for populations at-risk for e-cigarette use, particularly dual usage. Further, longitudinal epidemiological studies are needed to dissect the trajectory of respiratory symptoms development among e-cigarette users.

Our study may contribute to better understand the prevalence of respiratory symptoms among e-cigarette users. Given the rising popularity of e-cigarettes and their potential health implications, understanding the respiratory risks associated with their use is crucial for public health. These studies provide valuable insights into the prevalence, incidence, and impact of respiratory symptoms, helping to inform policies, interventions, and healthcare strategies aimed at mitigating potential health risks. By assessing the respiratory health of e-cigarette users, we can gain a better understanding of the potential harms and inform evidence-based approaches to protect and promote respiratory well-being in this population.

Limitations

While this systematic review presents notable insights into self-reported respiratory symptoms linked to e-cigarette use, several limitations warrant mentioning. First is the heterogeneity of the study samples, methodologies, and outcomes across the included studies for the meta-analysis. Second, this study did not encompass adolescent populations, a demographic that could potentially exhibit different e-cigarette use patterns compared to adults, and hence may display disparities in respiratory symptom prevalence warranting future investigation. A significant number of the symptoms were subjectively reported by the individuals rather than being identified using objective or observational metrics, which introduces the potential for recall and social desirability biases. As such, these symptoms require verification in larger and multicentric longitudinal

studies globally. This study did not differentiate between e-cigarettes, whether any of the included assessed modified e-cigarette cartridges and liquids and heated tobacco products in assessing their health effects, highlighting the need for future research to address this limitation and examine the specific health impacts of each product. Moreover, we have noted that individuals who use e-cigarettes may also have concurrent health conditions and a history of traditional smoking. Lastly, considering the high degree of heterogeneity observed among the studies, the majority of results were interpreted using a random-effects model. Hence, there is a need for higher-quality RCTs and prospective studies to assess causality, with a focus on exclusive e-cigarette use. Despite these limitations, this systematic review contributes to the expanding body of knowledge regarding the impact of e-cigarette use on respiratory health.

CONCLUSIONS

In this systematic review, our meta-analyses of exclusive e-cigarette users, dual e-cigarette users, and transitioning e-cigarette users demonstrated significant incidences of various respiratory symptoms, emphasizing the impact of e-cigarette usage on respiratory health and the need for further research in this area. Effective e-cigarette cessation interventions are needed to prevent respiratory symptoms and respiratory disease, and subsequently improve health outcomes. The results from this study will inform clinical recommendations/guidelines for e-cigarette users and dual users of e-cigarettes and traditional cigarettes.

REFERENCES

1. Mayer M, Reyes-Guzman C, Grana R, Choi K, Freedman ND. Demographic Characteristics, Cigarette Smoking, and e-Cigarette Use Among US Adults. *JAMA network open*. 2020;3(10):e2020694.
2. Chen PC, Chang LC, Hsu C, Lee YC. Dual Use of E-Cigarettes and Traditional Cigarettes Among Adolescents in Taiwan, 2014-2016. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2019;21(1):48-54.
3. Spindle TR, Hiler MM, Cooke ME, Eissenberg T, Kendler KS, Dick DM. Electronic cigarette use and uptake of cigarette smoking: A longitudinal examination of U.S. college students. *Addictive behaviors*. 2017;67:66-72.

4. Bravo-Gutiérrez OA, Falfán-Valencia R, Ramírez-Venegas A, Sansores RH, Ponciano-Rodríguez G, Pérez-Rubio G. Lung Damage Caused by Heated Tobacco Products and Electronic Nicotine Delivery Systems: A Systematic Review. *International journal of environmental research and public health*. 2021;18(8).
5. Armendáriz-Castillo I, Guerrero S, Vera-Guapi A, Cevallos-Vilatuña T, García-Cárdenas JM, Guevara-Ramírez P, et al. Genotoxic and Carcinogenic Potential of Compounds Associated with Electronic Cigarettes: A Systematic Review. *BioMed research international*. 2019;2019:1386710.
6. Gaur S, Agnihotri R. Health Effects of Trace Metals in Electronic Cigarette Aerosols-a Systematic Review. *Biological trace element research*. 2019;188(2):295-315.
7. Ward AM, Yaman R, Ebbert JO. Electronic nicotine delivery system design and aerosol toxicants: A systematic review. *PloS one*. 2020;15(6):e0234189.
8. Bjurlin MA, Matulewicz RS, Roberts TR, Dearing BA, Schatz D, Sherman S, et al. Carcinogen Biomarkers in the Urine of Electronic Cigarette Users and Implications for the Development of Bladder Cancer: A Systematic Review. *European urology oncology*. 2021;4(5):766-83.
9. Ralho A, Coelho A, Ribeiro M, Paula A, Amaro I, Sousa J, et al. Effects of Electronic Cigarettes on Oral Cavity: A Systematic Review. *The journal of evidence-based dental practice*. 2019;19(4):101318.
10. Yang I, Sandeep S, Rodriguez J. The oral health impact of electronic cigarette use: a systematic review. *Critical reviews in toxicology*. 2020;50(2):97-127.
11. Cardenas VM, Fischbach LA, Chowdhury P. The use of electronic nicotine delivery systems during pregnancy and the reproductive outcomes: A systematic review of the literature. *Tobacco induced diseases*. 2019;17:52.
12. Kennedy CD, van Schalkwyk MCI, McKee M, Pisinger C. The cardiovascular effects of electronic cigarettes: A systematic review of experimental studies. *Preventive medicine*. 2019;127:105770.
13. Gotts JE, Jordt SE, McConnell R, Tarran R. What are the respiratory effects of e-cigarettes? *BMJ (Clinical research ed)*. 2019;366:l5275.
14. Werner AK, Koumans EH, Chatham-Stephens K, Salvatore PP, Armatas C, Byers P, et al. Hospitalizations and Deaths Associated with EVALI. *The New England journal of medicine*. 2020;382(17):1589-98.
15. Williams M, Talbot P. Design Features in Multiple Generations of Electronic Cigarette Atomizers. *International journal of environmental research and public health*. 2019;16(16).
16. Gugala E, Okoh CM, Ghosh S, Moczygemba LR. Pulmonary Health Effects of Electronic Cigarettes: A Scoping Review. *Health promotion practice*. 2022;23(3):388-96.
17. Lerner CA, Rutagarama P, Ahmad T, Sundar IK, Elder A, Rahman I. Electronic cigarette aerosols and copper nanoparticles induce mitochondrial stress and promote DNA fragmentation in lung fibroblasts. *Biochemical and biophysical research communications*. 2016;477(4):620-5.
18. Schier JG, Meiman JG, Layden J, Mikosz CA, VanFrank B, King BA, et al. Severe Pulmonary Disease Associated with Electronic-Cigarette-Product Use - Interim Guidance. *MMWR Morbidity and mortality weekly report*. 2019;68(36):787-90.
19. Collaco JM, McGrath-Morrow SA. Electronic Cigarettes: Exposure and Use Among Pediatric Populations. *Journal of aerosol medicine and pulmonary drug delivery*. 2018;31(2):71-7.
20. Tran L, Tran P, Tran L. A cross-sectional analysis of electronic cigarette use in US adults by asthma status. *The clinical respiratory journal*. 2020;14(10):991-7.
21. Berlowitz JB, Xie W, Harlow AF, Blaha MJ, Bhatnagar A, Benjamin EJ, et al. Cigarette-E-cigarette Transitions and Respiratory Symptom Development. *American journal of preventive medicine*. 2023;64(4):556-60.
22. Cassidy RN, Tidey JW, Colby SM. Exclusive E-Cigarette Users Report Lower Levels of Respiratory Symptoms Relative to Dual E-Cigarette and Cigarette Users. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2020;22(Suppl 1):S54-s60.
23. Chatham-Stephens K, Law R, Taylor E, Kieszak S, Melstrom P, Bunnell R, et al. Exposure Calls to U. S. Poison Centers Involving Electronic Cigarettes and Conventional Cigarettes-September 2010-December 2014. *Journal of medical toxicology : official journal of the American College of Medical Toxicology*. 2016;12(4):350-7.
24. Culbreth RE, Spears CA, Brandenberger K, Feresin R, Self-Brown S, Goodfellow LT, et al. Dual Use of Electronic Cigarettes and Traditional Cigarettes Among Adults: Psychosocial Correlates and Associated Respiratory Symptoms. *Respiratory care*. 2021;66(6):951-9.
25. D'Ruiz CD, Graff DW, Yan XS. Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes. *BMC public health*. 2015;15:991.
26. Dai H, Khan AS. A Longitudinal Study of Exposure to Tobacco-Related Toxicants and Subsequent Respiratory Symptoms Among U.S. Adults with Varying E-cigarette Use Status. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2020;22(Suppl 1):S61-s9.
27. Dicpinigaitis PV, Lee Chang A, Dicpinigaitis AJ, Negassa A. Effect of e-Cigarette Use on Cough Reflex Sensitivity. *Chest*. 2016;149(1):161-5.
28. Dicpinigaitis PV, Lee Chang A, Dicpinigaitis AJ, Negassa A. Effect of Electronic Cigarette Use on the Urge-to-Cough Sensation. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2016;18(8):1763-5.

29. Jackson M, Singh KP, Lamb T, McIntosh S, Rahman I. Flavor Preference and Systemic Immunoglobulin Responses in E-Cigarette Users and Waterpipe and Tobacco Smokers: A Pilot Study. *International journal of environmental research and public health*. 2020;17(2).
30. King JL, Reboussin BA, Wiseman KD, Ribisl KM, Seidenberg AB, Wagoner KG, et al. Adverse symptoms users attribute to e-cigarettes: Results from a national survey of US adults. *Drug and alcohol dependence*. 2019;196:9-13.
31. Lee SM, Tenney R, Wallace AW, Arjomandi M. E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. *PeerJ*. 2018;6:e5609.
32. Li D, Sundar IK, McIntosh S, Ossip DJ, Goniewicz ML, O'Connor RJ, et al. Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2. *Tobacco control*. 2020;29(2):140-7.
33. Li Q, Zhan Y, Wang L, Leischow SJ, Zeng DD. Analysis of symptoms and their potential associations with e-liquids' components: a social media study. *BMC public health*. 2016;16:674.
34. Pratt SI, Sargent J, Daniels L, Santos MM, Brunette M. Appeal of electronic cigarettes in smokers with serious mental illness. *Addictive behaviors*. 2016;59:30-4.
35. Schneller LM, Quiñones Tavárez Z, Goniewicz ML, Xie Z, McIntosh S, Rahman I, et al. Cross-Sectional Association Between Exclusive and Concurrent Use of Cigarettes, ENDS, and Cigars, the Three Most Popular Tobacco Products, and Wheezing Symptoms Among U.S. Adults. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2020;22(Suppl 1):S76-s84.
36. Soule EK, Bode KM, Desrosiers AC, Guy M, Breland A, Fagan P. User-Perceived Negative Respiratory Symptoms Associated with Electronic Cigarette Use. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2020;22(Suppl 1):S45-s53.
37. Wang JB, Olgin JE, Nah G, Vittinghoff E, Cataldo JK, Pletcher MJ, et al. Cigarette and e-cigarette dual use and risk of cardiopulmonary symptoms in the Health eHeart Study. *PloS one*. 2018;13(7):e0198681.
38. Xie Z, Li D. Cross-Sectional Association Between Lifetime Use of Electronic Cigarettes With or Without Marijuana and Self-Reported Past 12-Month Respiratory Symptoms as well as Lifetime Respiratory Diseases in U.S. Adults. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2020;22(Suppl 1):S70-s5.
39. Yao T, Max W, Sung HY, Glantz SA, Goldberg RL, Wang JB, et al. Relationship between spending on electronic cigarettes, 30-day use, and disease symptoms among current adult cigarette smokers in the U.S. *PloS one*. 2017;12(11):e0187399.
40. Cravo AS, Bush J, Sharma G, Savioz R, Martin C, Craig S, et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. *Regulatory toxicology and pharmacology : RTP*. 2016;81 Suppl 1:S1-s14.
41. Dawkins L, Turner J, Roberts A, Soar K. 'Vaping' profiles and preferences: an online survey of electronic cigarette users. *Addiction (Abingdon, England)*. 2013;108(6):1115-25.
42. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. *New England journal of medicine*. 2019;380(7):629-37.
43. Tattan-Birch H, Kock L, Brown J, Beard E, Bauld L, West R, et al. E-cigarettes to Augment Stop Smoking In-person Support and Treatment With Varenicline (E-ASSIST): A Pragmatic Randomized Controlled Trial. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2023;25(3):395-403.
44. Walele T, Bush J, Koch A, Savioz R, Martin C, O'Connell G. Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. *Regulatory toxicology and pharmacology : RTP*. 2018;92:226-38.
45. Walele T, Sharma G, Savioz R, Martin C, Williams J. A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part B: Safety and subjective effects. *Regulatory toxicology and pharmacology : RTP*. 2016;74:193-9.
46. Wang RJ, Bhadriraju S, Glantz SA. E-Cigarette Use and Adult Cigarette Smoking Cessation: A Meta-Analysis. *American journal of public health*. 2021;111(2):230-46.
47. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. Efficiency and Safety of an eElectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. *PloS one*. 2013;8(6):e66317.
48. Polosa R, Caponnetto P, Maglia M, Morjaria JB, Russo C. Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. *BMC public health*. 2014;14:1159.
49. Polosa R, Caponnetto P, Morjaria J, Papale G, Campagna D, Russo C, et al. Effect of an electronic cigarette on smoking cessation and reduction: A prospective pilot study. *European Respiratory Journal*. 2011;38. Accessed October 26, 2023. https://erj.ersjournals.com/content/38/Suppl_55/p1074
50. Polosa R, Morjaria JB, Caponnetto P, Campagna D, Russo C, Alamo A, et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. *Internal and emergency medicine*. 2014;9(5):537-46.
51. Skucha W, Mejza F, Nastalek P, Doniec Z. Pulmonary prevention program in the Proszowice county:

- description and results. *Advances in respiratory medicine*. 2017;85(5):239-45.
52. Diamantopoulou E, Barbouni A, Merakou K, Lagiou A, Farsalinos K. Patterns of e-cigarette use, biochemically verified smoking status and self-reported changes in health status of a random sample of vapes shops customers in Greece. *Internal and emergency medicine*. 2019;14(6):843-51.
 53. Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V. Evaluating nicotine levels selection and patterns of electronic cigarette use in a group of “vapers” who had achieved complete substitution of smoking. *Substance Abuse: Research and Treatment*. 2013;7:139-46.
 54. Mohamed MHN, Rahman A, Jamshed S, Mahmood S. Effectiveness and safety of electronic cigarettes among sole and dual user vapers in Kuantan and Pekan, Malaysia: a six-month observational study. *BMC public health*. 2018;18(1):1028.
 55. Puteh SEW, Manap RA, Hassan TM, Ahmad IS, Idris IB, Sham FM, et al. The use of e-cigarettes among university students in Malaysia. *Tobacco induced diseases*. 2018;16:57.
 56. Lee WK, Smith CL, Gao CX, Borg BM, Nilsen K, Brown D, et al. Are e-cigarette use and vaping associated with increased respiratory symptoms and poorer lung function in a population exposed to smoke from a coal mine fire? *Respirology (Carlton, Vic)*. 2021;26(10):974-81.
 57. Chaiton M, Pienkowski M, Musani I, Bondy SJ, Cohen JE, Dubray J, et al. Smoking, e-cigarettes and the effect on respiratory symptoms among a population sample of youth: Retrospective cohort study. *Tobacco induced diseases*. 2023;21:08.
 58. Habib E, Helaly M, Elshaer A, Sriwi D, Ahmad MS, Mohamed MI, et al. Prevalence and perceptions of e-cigarette use among medical students in a Saudi University. *Journal of family medicine and primary care*. 2020;9(6):3070-5.
 59. Lestari KS, Humairo MV, Agustina U. Formaldehyde Vapor Concentration in Electronic Cigarettes and Health Complaints of Electronic Cigarettes Smokers in Indonesia. *Journal of environmental and public health*. 2018;2018:9013430.
 60. Etter JF. Electronic cigarettes: a survey of users. *BMC public health*. 2010;10:231.
 61. Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V. Characteristics, perceived side effects and benefits of electronic cigarette use: A worldwide survey of more than 19,000 consumers. *International journal of environmental research and public health*. 2014;11(4):4356-73.
 62. Soule EK, Nasim A, Rosas S. Adverse Effects of Electronic Cigarette Use: A Concept Mapping Approach. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2016;18(5):678-85.
 63. Li D, Xie Z. Cross-Sectional Association of Lifetime Electronic Cigarette Use with Wheezing and Related Respiratory Symptoms in U.S. Adults. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2020;22(Suppl 1):S85-s92.
 64. Li D, Sundar IK, McIntosh S, Ossip DJ, Goniewicz ML, O'Connor RJ, et al. Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2. *Tobacco control*. 2019.
 65. Polosa R, Caponnetto P, Morjaria JB, Papale G, Campagna D, Russo C. Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. *BMC public health*. 2011;11:786.
 66. Rahman A, Mohamad MHN, Jamshed S. Evaluating effectiveness and safety toward electronic cigarette among Malaysian vapers: One-month observational study. *Archives of Pharmacy Practice*. 2016;7(2):43-53.
 67. Creamer MR, Wang TW, Babb S, Cullen KA, Day H, Willis G, et al. Tobacco Product Use and Cessation Indicators Among Adults - United States, 2018. *MMWR Morbidity and mortality weekly report*. 2019;68(45):1013-9.
 68. Davidson K, Brancato A, Heetderks P, Mansour W, Matheis E, Nario M, et al. Outbreak of Electronic-Cigarette-Associated Acute Lipoid Pneumonia - North Carolina, July-August 2019. *MMWR Morbidity and mortality weekly report*. 2019;68(36):784-6.
 69. Cavazos-Rehg PA, Krauss MJ, Spitznagel EL, Grucza RA, Bierut LJ. Youth tobacco use type and associations with substance use disorders. *Addiction (Abingdon, England)*. 2014;109(8):1371-80.
 70. Chun LF, Moazed F, Calfee CS, Matthay MA, Gotts JE. Pulmonary toxicity of e-cigarettes. *American journal of physiology Lung cellular and molecular physiology*. 2017;313(2):L193-L206.
 71. Eaton DL KL, Stratton K, editors. *Public Health Consequences of E-Cigarettes*. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems; : Washington (DC): National Academies Press (US); 2018 Jan 23.
 72. Zhang YY, Bu FL, Dong F, Wang JH, Zhu SJ, Zhang XW, et al. The effect of e-cigarettes on smoking cessation and cigarette smoking initiation: An evidence-based rapid review and meta-analysis. *Tobacco induced diseases*. 2021;19:04.
 73. Allehebi RO, Khan M, Stanbrook MB. Efficacy and safety of electronic cigarettes for smoking cessation: A systematic review. *American Journal of Respiratory and Critical Care Medicine*. 2015;191. Accessed October 23, 2023. <https://www.atsjournals.org/doi/abs/10.1164/>

ajrccm-conference.2015.191.1_MeetingAbstracts.A3715?download=true

74. Farber HJ, Conrado Pacheco Gallego M, Galiatsatos P, Folan P, Lamphere T, Pakhale S. Harms of Electronic Cigarettes: What the Healthcare Provider Needs to Know. *Annals of the American Thoracic Society*. 2021;18(4):567-72.

CONFLICTS OF INTEREST

The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.

FUNDING

There was no source of funding for this research.

ETHICAL APPROVAL AND INFORMED CONSENT

Ethical approval and informed consent were not required for this study.

DATA AVAILABILITY

The data supporting this research are available from the authors on reasonable request.

AUTHORS' CONTRIBUTIONS

MMA: literature review, study design, data analysis, prepared the first draft of the current manuscript; FKA and MAA: data analysis and manuscript preparation; AMA: review and drafting of this manuscript, data analysis; ZBT, HA, SSA, TFA and MKA: review and drafting of this manuscript; MEEK: edit and review of this manuscript; MPM and RZM: research review, manuscript preparation; RC and LTG: writing of the discussion section and data analysis; MA: drafting of this paper; TTI: data analysis and critique; Hal: writing of the manuscript and data analysis; NSA: data analysis and interpretation; EF: supervised this study throughout all of its part.

PROVENANCE AND PEER REVIEW

Not commissioned; externally peer reviewed.